دورية أكاديمية
[A DNA medication pass for everyone?]
| العنوان: | [A DNA medication pass for everyone?] |
|---|---|
| عنوان ترانسليتريتد: | Iedereen een DNA-medicatiepas? |
| المؤلفون: | Vos CNF; Radboudumc, afd. Psychiatrie, Nijmegen.; Contact: Cornelis (Niels) F. Vos (niels.vos@radboudumc.nl)., De Wildt SN; Radboudumc, afd. Farmacologie-Toxicologie, Nijmegen (tevens: Erasmusmc, Sophia kinderziekenhuis, Rotterdam)., Kramers CK; Radboudumc, afd. Farmacologie-Toxicologie, Nijmegen. |
| المصدر: | Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2023 Apr 19; Vol. 167. Date of Electronic Publication: 2023 Apr 19. |
| نوع المنشور: | Randomized Controlled Trial; English Abstract; Journal Article |
| اللغة: | Dutch; Flemish |
| بيانات الدورية: | Publisher: Vereniging NTvG Country of Publication: Netherlands NLM ID: 0400770 Publication Model: Electronic Cited Medium: Internet ISSN: 1876-8784 (Electronic) Linking ISSN: 00282162 NLM ISO Abbreviation: Ned Tijdschr Geneeskd Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2017?-: Amsterdam : Vereniging NTvG Original Publication: Houten : Bohn Stafleu van Loghum |
| مواضيع طبية MeSH: | Pharmacogenetics*/methods , Precision Medicine*/methods, Humans ; Genotype ; Anticoagulants ; DNA |
| مستخلص: | Pharmacogenetics holds the promise of personalized medicine, resulting in higher effectiveness and fewer adverse effects. Yet, the clinical benefit of a pre-emptive pharmacogenetic test has not been demonstrated rigorously. Recently an open-label real-world implementation study has been published, in which patients were randomized to either genotype-informed treatment (based on a 12-gene pharmacogenetic panel) or standard treatment. The study shows that genotype-informed prescription of different types of medication, i.e., opioids, anticoagulants and antidepressants, leads to a 30% reduction of clinically relevant adverse effects. This result is promising and indicates that genotype-informed treatment improves medication safety. Unfortunately, the influence of genotype-informed treatment on the balance between effectiveness and adverse effects could not be assessed and cost-effectiveness data are pending. Hence, a pharmacogenetic panel and a DNA medication pass for everyone are on the horizon, but not yet there. |
| المشرفين على المادة: | 0 (Anticoagulants) 9007-49-2 (DNA) |
| تواريخ الأحداث: | Date Created: 20230420 Date Completed: 20230421 Latest Revision: 20230424 |
| رمز التحديث: | 20230502 |
| PMID: | 37078568 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1876-8784 |
|---|